Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer

• ClinicalTrials.gov Identifier: NCT05415943
• Recruitment Status: Completed
• First Posted: June 13, 2022
• Last Update Posted: March 9, 2023
• Sponsor: SDS Optic S.A.
• Information provided by (Responsible Party): SDS Optic S.A.

Study Description

Brief Summary:

The purpose of this study is to preliminarily determine the correlation of HER2 receptor levels detected with the inPROBE diagnostic probe relative to receptor status as determined by standard methods (IHC/FISH), in women with both HER2-positive and HER2-negative breast cancer.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Device: Diagnostic microprobe (inPROBE) medical device	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 18 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: An Open-label, Multicentre, Single-arm Safety and Efficacy Clinical Investigation of Diagnostic Microprobe (inPROBE) for the Assessment of HER2 Receptor Expression in Population of Women at High Risk of Breast Cancer
• Actual Study Start Date: August 24, 2022
• Actual Primary Completion Date: March 2, 2023
• Actual Study Completion Date: March 2, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Women at high risk of breast cancer; Women with a confirmed diagnosis of breast cancer by thick-needle biopsy and known HER2 receptor expression status, referred for surgical treatment.	Device: Diagnostic microprobe (inPROBE) medical device; Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.

Outcome Measures

Primary Outcome Measures :

1. Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH). [ Time Frame: Day 1 ]

Secondary Outcome Measures :

1. The occurrence of defects, failures, and fractures of the inPROBE probe during the diagnostic procedure leading to AE/ SAE. [ Time Frame: Day 1 - Day 14 ]
2. Comparison of the correlation of HER2 receptor concentrations detected by the inPROBE probe located in the tumor and in the immediate tumor area in HER2 positive patients. [ Time Frame: Day 1 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Provision of written informed consent to participate in the clinical investigation;
2. Female patient aged ≥ 18 to ≤ 75 years;
3. The patient's overall health status as determined by Eastern Cooperative Oncology Group (ECOG) from 0 to 1;
4. Preserved full ability to communicate with the investigator and to understand and comply with the requirements of the Clinical investigation plan;
5. High likelihood of attending follow-up appointments in accordance with the study design and completing this study in accordance with this Clinical investigation plan.
6. The presence of a malignant neoplasm (breast cancer) confirmed by histopathologic examination of material from a gross needle biopsy of the tumor, with specific HER2 receptor status.
7. Patient referred for surgical treatment of breast cancer.

Exclusion Criteria:

1. History of treatment with trastuzumab, or other HER 2 receptor-binding antibody, as part of neoadjuvant (induction) therapy for currently diagnosed and treated breast cancer.
2. A skin disorder that prevents or contraindicates to perform a probe examination in the opinion of the investigator;
3. Breast inflammation/infection on the day of the probe examination;
4. Allergy to any component of the medical device that is the subject of this clinical investigation;
5. An implant in the breast where the inPROBE study and surgery will be performed;
6. Any physical or psychiatric condition, or laboratory test values outside the normal range, which in the opinion of the investigator constitute a contraindication to the patient's participation in this clinical investigation or pose a risk of exclusion from the study or premature termination of participation in the study;
7. Any clinically significant abnormality in physical examination, vital signs, or laboratory tests that, in the opinion of the investigator, is a contraindication to participation in this clinical trial;
8. Pregnancy or breastfeeding;
9. Participation in another clinical trial within 30 days prior to signing informed consent to participate in this clinical investigation;

Contacts and Locations

Locations

Poland

Uniwersyteckie Centrum Leczenia Chorób Piersi, Szpital Uniwersytecki w Krakowie

Kraków, Poland, 30-688

Klinika Chirurgii Onkologicznej

Lublin, Poland, 20-081

Sponsors and Collaborators

SDS Optic S.A.

More Information

• Responsible Party: SDS Optic S.A.
• ClinicalTrials.gov Identifier: NCT05415943
• Other Study ID Numbers: SDS-HER-01-2018
• First Posted: June 13, 2022
• Last Update Posted: March 9, 2023
• Last Verified: March 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases